Alexandria Real Estate Equities Earnings Call Transcripts
Fiscal Year 2026
-
Operational progress continued despite a tough quarter, with strong asset quality and tenant base, but leasing volume and occupancy declined due to market headwinds. Guidance for FFO per share and dispositions was reaffirmed, while tenant risk and lease expirations remain key watch points.
Fiscal Year 2025
-
Q4 2025 saw record leasing and $1.5B in dispositions, with occupancy at 90.9% and FFO per share at $2.16. 2026 guidance anticipates a temporary dip in occupancy and NOI, with recovery in the second half, and a focus on asset sales and balance sheet strength.
-
Management is executing a strategic shift to focus on mega campuses, reduce non-core assets, and strengthen the balance sheet amid industry headwinds. 2026 guidance reflects lower occupancy and NOI, but the company expects to outperform peers and capitalize on long-term demand drivers like innovation and healthcare needs.
-
FFO per share declined to $2.22 in Q3 2025, with occupancy dropping to 90.6% and guidance for 2025 and 2026 earnings reduced due to lower investment gains, slower leasing, and ongoing industry headwinds. Strategic focus remains on mega campuses and reducing non-income-producing assets.
-
Achieved record leasing with a 466,000 sq ft build-to-suit for a top pharma, driving solid FFO growth and maintaining strong occupancy guidance. Asset recycling and cost discipline continue, while sector resilience is supported by robust M&A and venture funding.
-
Q1 2025 saw strong leasing, high rent collections, and solid financial results, with revenues up 4% and adjusted EBITDA up 5% year-over-year. Guidance was modestly reduced due to slower lease-up and occupancy declines, but the balance sheet remains robust and asset recycling continues to fund growth.
Fiscal Year 2024
-
FFO per share grew 5.6% in 2024, with strong leasing, capital recycling, and high occupancy. Guidance for 2025 is flat FFO per share, with continued focus on mega campuses, asset recycling, and disciplined capital allocation.
-
Mega campus strategy drives long-term growth, with 2025 FFO per share guidance flat year-over-year due to temporary vacancies. Self-funding through cash flow and asset sales supports $510 million in incremental NOI by 2028, while leasing outperformance and premium rents reinforce competitive advantage.
-
Q3 2024 saw robust financial and operational results, with strong leasing, high occupancy, and significant asset recycling to fund the mega campus strategy. Guidance for FFO per share growth is maintained, and the balance sheet remains strong amid disciplined capital allocation and a resilient life science market.
-
Q2 2024 saw strong FFO and NOI growth, robust leasing, and continued execution of the mega campus strategy, with high occupancy and a focus on asset recycling. The life science sector remains well-funded and innovative, though supply and demand dynamics vary by submarket.